U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

@article{Claro2012USFA,
  title={U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.},
  author={R. Angelo de Claro and Karen M McGinn and Virginia E. Kwitkowski and Julie Bullock and Aakanksha Khandelwal and Bahru Habtemariam and Yanli Ouyang and Haleh Saber and Kyung Lee and Kallappa M. Koti and Mark D. Rothmann and Marjorie Shapiro and Francisco Borrego and Kathleen A. Clouse and Xiao Hong Chen and Janice Brown and Lara Akinsanya and Robert Kane and Edvardas Kaminskas and A. Vallely Farrell and Richard Pazdur},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2012},
  volume={18 21},
  pages={5845-9}
}
The U.S. Food and Drug Administration (FDA) describes the accelerated approval of brentuximab vedotin for patients with relapsed Hodgkin lymphoma and relapsed systemic anaplastic large-cell lymphoma (sALCL). FDA analyzed the results of two single-arm trials, enrolling 102 patients with Hodgkin lymphoma and 58 patients with sALCL. Both trials had primary endpoints of objective response rate (ORR) and key secondary endpoints of response duration and complete response (CR) rate. For patients with… CONTINUE READING
46 Citations
15 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

SEER cancer statistics review, 1975–2008

  • N Howlader, AM Noone, +4 authors editors
  • Bethesda (MD): National Cancer Institute;
  • 2011
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…